Actovegin

01/01/2017 - "ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment."
01/01/2013 - "Efficacy of actovegin was investigated in the treatment of mild cognitive impairment (MCI) of cerebrovascular genesis. "
01/01/2013 - "[Efficacy of actovegin in the treatment of elderly patients with vascular mild cognitive impairment]."
12/30/2018 - "The study of Actovegin effectin clinical presentations and hemorheological characteristics in patients with chronic cerebrovascular pathology (CCVP) and mild cognitive impairment. "
01/01/2017 - "Actovegin had a beneficial effect on cognitive outcomes in patients with poststroke cognitive impairment. "

10/01/2008 - "These data lead to the conclusion that Actovegin is effective in the treatment of patients with ischemic stroke."
01/01/2022 - "More evidence is needed from rigorously designed clinical trials to justify the role of Actovegin in patients with ischemic stroke."
01/01/2017 - "The aim of this study was to assess whether Actovegin confers cognitive benefit in patients who have had an ischemic stroke. "
01/01/2022 - "To perform a systematic review to evaluate the effect of Actovegin in patients who have suffered an ischemic stroke. "
01/01/2022 - "Actovegin in the management of patients after ischemic stroke: A systematic review."

01/01/2022 - "The benefits of Actovegin are uncertain and that there is potential risk of harm in patients with stroke. "
01/01/2013 - "The study consists of a baseline screening (≤7 days after stroke), after which eligible patients are randomised to Actovegin (2,000 mg/day for up to 20 intravenous infusions followed by 1,200 mg/day orally) or placebo for a 6-month double-blind treatment period. "
01/01/2015 - "[The measures of autonomic homeostasis as predictors of an individual risk of stroke and their dynamics during therapy with actovegin]."
01/01/2013 - "A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design."
10/01/2008 - "Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke."

01/01/2008 - "[Efficacy of actovegin in the treatment of cognitive disturbances in discirculatory encephalopathy]."
01/01/1991 - "A study was made of microcirculation using bulbar biomicroscopy and of the aggregation properties of platelets in 94 patients with initial manifestations of cerebral circulatory failure and dyscirculatory encephalopathy before and after the treatment with vasoactive drugs and actovegin. "
01/01/1994 - "[Combined therapy using actovegin and instenon in encephalopathies of different origins]."

10/01/2010 - "Actovegin is effective in the prevention and treatment of chemoradiotherapy-induced oral mucositis."
10/01/2010 - "A multi-center prospective randomized trial was conducted to evaluate the efficacy and safety of Actovegin in the prevention and treatment of chemoradiotherapy-induced acute oral mucositis. "
02/01/2021 - "PURPOSE： To explore the clinical effect of Actovegin in the treatment of acute oral mucositis in patients with radiotherapy. "
10/01/2010 - "A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma."
02/01/2021 - "CONCLUSIONS: Actovegin has a clear clinical effect on acute oral mucositis in patients with radiotherapy, which can significantly alleviate the pain of patients and reduce the level of serum inflammatory factors."